James Smith
Houston, TXNPI 1023078052
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 79.9% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $19,786 and has fallen 98.4% since, to $320 in 2025.
Across 456 payments — averaging $93.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$34K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$926
- Otsuka America Pharmaceutical, Inc.$874
- Teva Pharmaceuticals USA, Inc.$534
- plus $2K from 18 others
What the payments were for
- Consulting fees$11,61927%
- Speaking & faculty fees$20,62548%
- Travel & lodging$1,9465%
- Food & beverage$8,31019%
- Education$1510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 67 | $34,089 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $2,791 |
| AbbVie | 84 | $1,210 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 44 | $926 |
| Otsuka America Pharmaceutical, Inc. | 59 | $874 |
| Teva Pharmaceuticals USA, Inc. | 28 | $534 |
| Alkermes, Inc. | 29 | $468 |
| Lundbeck LLC | 29 | $419 |
| Corium, LLC | 16 | $222 |
| Bausch Health US, LLC | 14 | $217 |
| Johnson & Johnson | 5 | $186 |
| Axsome Therapeutics, Inc. | 8 | $144 |
| Sunovion Pharmaceuticals Inc. | 5 | $109 |
| Tris Pharma Inc | 5 | $97 |
| Noven Therapeutics, LLC | 3 | $69 |
| Ironshore Pharmaceuticals Inc. | 3 | $63 |
| Biogen | 1 | $60 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Almatica Pharma LLC | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Medtronic | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$29,612
- TRINTELLIX$2,150
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 20 | $403 |
| Trazodone Hcl | 26 | $253 |
| Duloxetine Hcl | 11 | $209 |
| Lamotrigine | 24 | $55 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.